New drugs to treat hepatitis C are expected to be approved over the next few years which
promise to cure nearly all patients. However, due to issues of expected drug resistance …

Unless urgently needed to prevent a pandemic, the development of a viral vaccine should
follow a rigorous scientific approach. Each vaccine candidate should be designed …

Approximately 170 million individuals, representing 3% of the global population, are infected
with hepatitis C virus (HCV). Whereas strategies for antiviral therapies have markedly …

Introduction: Around 3% of the world population is infected with HCV, with 3–4 million newly
infected subjects added to this reservoir every year. At least 10% of these people will …

Introduction: With 3–4 million new infections occurring annually, hepatitis C virus (HCV) is a
major global health problem. There is increasing evidence to suggest that HCV will be …

Hepatitis C virus (HCV) was first identified in 1989. HCV is a small, enveloped RNA virus.
Globally, 3–4 million persons are infected with HCV each year, and are at risk of developing …

The hepatitis C virus (HCV) causes both acute and chronic infection and continues to be a
global problem despite advances in antiviral therapeutics. Current treatments fail to prevent …

Hepatitis C virus (HCV) is a blood borne disease estimated to chronically infect 3% of the
worlds' population causing significant morbidity and mortality. Current medical therapy is …

Given the global disease burden and public health impact of hepatitis C, the development of
an effective vaccine is of paramount importance. However, many challenging obstacles …

Natural cross-protective immunity is induced after spontaneous clearance of primary
hepatitis C virus (HCV) infection. Although this suggests that effective prophylactic vaccines …